Clinical Cancer Research, Vol 1, Issue 11 1235-1244, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments

P Pantazis
The Stehlin Foundation for Cancer Research, St. Joseph Hospital, Houston, Texas 77003, USA.

Water-insoluble camptothecin (CPT) congeners are rapidly establishing themselves as promising anticancer drugs. In vitro, they have exhibited: (a) insensitivity to elevated levels of P-glycoprotein that confers multidrug resistance; (b) selective killing of malignant cells traversing the S-phase of the cell cycle, while leaving viable normal cells, which either are arrested at the S-G2 boundary or continue to divide; (c) no cross-resistance with several other anticancer drugs; and (d) potentiation or enhancement of cytotoxicity when appropriately used in combination with tumor necrosis factor, ionizing radiation, and hyperthermia. In addition, development of cell resistance to water-insoluble CPT congeners in vitro is accompanied by increased sensitivity to other anticancer drugs. Furthermore, water-insoluble CPT congeners have exhibited an unprecedented activity against a wide variety of human tumors xenografted in nude mice by inhibiting growth and inducing regression of carcinomas of the lung, breast, ovary, colon, stomach, pancreas, and prostate, as well as malignant melanoma, lymphoma, and leukemia. More importantly, oral administration of the water-insoluble CPT congeners in clinical studies with cancer patients makes other route(s) of administration unnecessary.

This article has been cited by other articles:

				D. Chatterjee, I. Schmitz, A. Krueger, K. Yeung, S. Kirchhoff, P. H. Krammer, M. E. Peter, J. H. Wyche, and P. Pantazis Induction of Apoptosis in 9-Nitrocamptothecin-treated DU145 Human Prostate Carcinoma Cells Correlates with de Novo Synthesis of CD95 and CD95 Ligand and Down-Regulation of c-FLIPshort Cancer Res., October 1, 2001; 61(19): 7148 - 7154. [Abstract] [Full Text] [PDF]

				M.-L. Li, L. Horn, P. S. Firby, and M. J. Moore Pharmacological Determinants of 9-Aminocamptothecin Cytotoxicity Clin. Cancer Res., January 1, 2001; 7(1): 168 - 174. [Abstract] [Full Text]

				Z. CAO, P. FANTAZIS, J. MENDOZA, J. EARLY, A. KOZIELSKI, N. HARRIS, D. VARDEMAN, J. LIEHR, J. S. STEHLIN, and B. GIOVANELLA Structure-Activity Relationship of Alkyl Camptothecin Esters Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 122 - 135. [Abstract] [Full Text] [PDF]